2018 CME/CE HTC NetWorkShops™: Update on Clinical Challenges and Key Management Issues in the Treatment of Hemophilia

Click the “Register” button to indicate you have reviewed the CME/CE information for this activity.

Minimum System Requirements:
  • Internet Explorer 10 (or higher)
  • Mozilla Firefox 48 (or higher)
  • Google Chrome (latest version)
  • Adobe Acrobat 15.0 (or higher)
  • Screen resolution 1024 x 768
Click here to contact Postgraduate Institute for Medicine (PIM)

2018 CME NetWorkShopsTM Schedule:

Thursday, November 15th, 2018  
7:00pm ET ♦ 6:00pm CT ♦ 5:00pm MT ♦ 4:00pm PT*
Presenter: Miguel Escobar, MD

Target Audience
This activity has been designed to meet the educational needs of hematologists, physicians, physician assistants, nurse practitioners, advanced practice registered nurses, registered nurses, and other specialists of the hemophilia treatment center (HTC) team, as well as other healthcare providers interested in the comprehensive care of patients with congenital or acquired hemophilia.

Statement of Need/Program Overview
Hemophilia is the most common severe inherited bleeding disorder recognized in humans, and it comprises the largest proportion of patients followed in most bleeding disorders clinics and HTCs.

Many of the clinicians who practice at HTCs or other types of hemophilia practices are not able to regularly attend the major national and international society meetings. They thus miss opportunities to keep abreast of the latest medical developments and to interact with experts who provide perspective and insight on a range of clinical challenges and patient management issues frequently encountered in the HTC setting.

With the CME/CE NetWorkShops™ series, however, these meetings can be brought to busy clinicians in the form of webcasts and organized group workshops at or near HTCs. Healthcare professionals are now able to view, analyze, and discuss key meeting findings with recognized hemophilia experts while gaining ideas on how to apply new learnings to their own clinical practice.

Educational Objectives
After participating in this activity, participants should be better able to:

  • Review new demographic and clinical data about the comprehensive care of patients with hemophilia (PWH)
  • Review developments in hemophilia treatment, including newer factor concentrates; prophylactic strategies and the potential of gene therapy; new and emerging models of care; inhibitor detection, eradication, and management; and addressing joint functioning and pain management
  • Implement individualized hemophilia management strategies that optimize adherence, outcomes, and preference‐based utilization of resources, which include shared decision‐making by the caregiver/patient
  • Assess pain and functional impairment by utilizing patient reported outcomes instruments to achieve improved health-related quality of life in PWH

Planning Committee and Presenting Faculty

Amy D. Shapiro, MD
Amy D. Shapiro, MD

Adjunct Professor, Pediatrics
Michigan State University
East Lansing, Michigan
Medical Director & Pediatric Hematologist
Indiana Hemophilia & Thrombosis Center
Indianapolis, Indiana


Miguel A. Escobar, MD
Miguel A. Escobar, MD
Department of Pediatrics and Internal Medicine
Division of Hematology
University of Texas and MD Anderson Cancer Center
McGovern Medical School
Medical Director, Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Steven W. Pipe, MD
Steven W. Pipe, MD
Professor of Pediatrics and Pathology
Laurence A. Boxer Research Professor of Pediatrics and Communicable Diseases
Pediatric Medical Director, Hemophilia and Coagulation Disorders Program
Director, Special Coagulation Laboratory
University of Michigan
Ann Arbor, Michigan

Robert Sidonio Jr, MD
Robert Sidonio Jr, MD
Associate Director of Hemostasis and Thrombosis
Comprehensive Bleeding Disorder Center at
Emory University and Children’s Healthcare of Atlanta
Atlanta, Georgia

Program Agenda
40-minute live webcast presentation
20-minute interactive question-and-answer session

Continuing Medical Education

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, the Cardiovascular & Metabolic Health Foundation, and Educational Concepts in Medicine. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine (PIM) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.

Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.0 contact hours.

Fee Information
There is no fee for this educational activity.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within 3 weeks (if applicable).

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Miguel A. Escobar, MD Consulting Fees: Bayer, CSL Behring, Genentech, HEMA Biologics, Novo Nordisk, Shire.
Contracted Research: Bayer, Biogen Idec, CSL Behring, Genentech, Novo Nordisk, Octapharma, OPKO Biologics, Pfizer, Shire.
Steven W. Pipe, MD Consulting Fees: Alnylam, Biogen Idec, CSL Behring, HEMA Biologics, Novo Nordisk, Pfizer, Roche/Genentech, Shire, uniQure.
Contracted Research: Siemens, Shire.
Amy D. Shapiro, MD Consulting Fees: Baxalta/Shire, Bayer, Biogen Idec, Bio Products Laboratory, Genentech, Kedrion, Prometic Life Sciences, Sangamo Biosciences, Novo Nordisk, Pfizer.
Contracted Research: Baxalta/Shire, Biogen Idec, CSL Behring, Daiichi Sankyo, Kedrion, Novo Nordisk, Octapharma, OPKO Biologics, Prometic Life Sciences.

Note: All honoraria and income are paid to the Indiana Hemophilia & Thrombosis Center. Dr Shapiro has no financial interest in any of the above listed companies.
Robert Sidonio Jr, MD Consulting Fees: Baxalta, Biogen Idec, CSL Behring, Emergent Solutions, Grifols, LFB, Novo Nordisk, Pfizer.
Contracted Research: Biogen Idec

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner or Manager Reported Financial Relationship
PIM Clinical Reviewers: Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, RN, BSN; Jan Schultz, RN, MSN, CHCP Have no real or apparent conflicts of interest to report.
ECM: Patrick J. Crowley, MBA, Managing Partner/CEO; Jodi Andrews, BS, Partner/COO;
Jo-Ann Angelucci, BA, Program Director
Have no real or apparent conflicts of interest to report.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. PIM and Educational Concepts in Medicine do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

This activity is supported by educational grants from Novo Nordisk Inc., Aptevo Therapeutics Inc., and Diplomat Specialty Infusion Group.